Zayed Rashid

Zayed Rashid

Auto-generated profile, based on publicly available information

Zayed Rashid

Department of Internal Medicine Conemaugh Memorial Medical Center Johnstown Pennsylvania USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Liver International
Verified
Journal Article
Open access
ZRZayed Rashid
Zayed Rashid
SWSelamawit Woldesenbet
Selamawit Woldesenbet
MKMujtaba Khalil
Mujtaba Khalil
SISidharth Iyer
Sidharth Iyer
MKMuhammad Muntazir Mehdi Khan
Muhammad Muntazir Mehdi Khan
Tim PawlikTim Pawlik
Tim Pawlik
Background and Aims: We sought to characterise the impact of GLP‐1RA on adverse liver outcomes (ALO) among patients with alcohol‐associated liver disease (ALD) and Type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM newly diagnosed with ALD between 2013 and 2020 were identified using IBM MarketScan database and were categorised by GLP‐1RA exposure. Overlap propensity score weighting (OPSW) followed by Poisson regression models was used to analyse adjusted risk of ALO, a composite endpoint defined by first occurrence of hepatic decompensation (HD), portal hypertension (PH), hepatocellular carcinoma (HCC) or liver transplantation (LT) relative to GLP‐1RA. Results: Among 14 730 patients, most individuals were male ( n = 9752, 66.2%) with median age of 57 (IQR 52–61) years; 2.2% ( n = 317) of patients had GLP‐1RA exposure. Overall, 32.0% ( n = 4717) of patients experienced HD, 15.9% ( n = 2345) had PH, 3.8% ( n = 563) developed HCC, while 2.5% ( n = 374) underwent transplantation. Non‐GLP‐1RA patients had higher incidence of HD (32.2% vs. 22.4%) and HCC (3.9% vs. 0.3%) versus patients taking GLP‐1RA (both p < 0.001); in contrast, there was no difference in incidence of PH (14.5% vs. 16.0%) and LT (1.3% vs. 2.6%) (both p > 0.05). After OPSW, overall incidence of ALO was lower in GLP‐1RA cohort (GLP‐1RA: 12.0%, 95%CI 9.0–16.0 vs. non‐GLP‐1RA: 21.0%, 95%CI 20.0–22.0) with an absolute incidence risk reduction of 9.0% (95%CI 3.0%–15.0%) associated with GLP‐1RA. GLP‐1RA was most strongly associated with lower likelihood of HD with reduced adjusted incidence rate of 0.56 (95%CI 0.36–0.86) relative to non‐GLP‐1RA individuals. Conclusions: GLP‐1RA may have a hepatoprotective impact among patients with ALD and T2DM.

16 May 2024 in HPB
Verified
Journal Article
Closed access
AAAbdullah Altaf
Abdullah Altaf
Yutaka EndoYutaka Endo
Yutaka Endo
MMMuhammad M. Munir
Muhammad M. Munir
MKMuhammad Muntazir M. Khan
Muhammad Muntazir M. Khan
ZRZayed Rashid
Zayed Rashid
Tim PawlikTim Pawlik
Tim Pawlik

1 April 2024 in Surgery
Verified
Journal Article
Closed access
ZRZayed Rashid
Zayed Rashid
MMMuhammad Musaab Munir
Muhammad Musaab Munir
SWSelamawit Woldesenbet
Selamawit Woldesenbet
Diamantis I. TsilimigrasDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
MKMujtaba Khalil
Mujtaba Khalil
Tim PawlikTim Pawlik
Tim Pawlik

27 November 2024 in HPB
Verified
Journal Article
Closed access
JKJun Kawashima
Jun Kawashima
AAAbdullah Altaf
Abdullah Altaf
Yutaka EndoYutaka Endo
Yutaka Endo
SWSelamawit Woldesenbet
Selamawit Woldesenbet
Diamantis I. TsilimigrasDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
Tim PawlikTim Pawlik
Tim Pawlik

20 December 2024 in HPB
Verified
Journal Article
Closed access
AAAbdullah Altaf
Abdullah Altaf
MMMuhammad M. Munir
Muhammad M. Munir
MKMuhammad Muntazir M. Khan
Muhammad Muntazir M. Khan
ZRZayed Rashid
Zayed Rashid
MKMujtaba Khalil
Mujtaba Khalil
Tim PawlikTim Pawlik
Tim Pawlik

10 May 2024 in Surgery
Verified
Journal Article
Closed access
MKMuhammad Muntazir Mehdi Khan
Muhammad Muntazir Mehdi Khan
MMMuhammad Musaab Munir
Muhammad Musaab Munir
MKMujtaba Khalil
Mujtaba Khalil
DTDiamantis I. Tsilimigras
Diamantis I. Tsilimigras
SWSelamawit Woldesenbet
Selamawit Woldesenbet
Tim PawlikTim Pawlik
Tim Pawlik